How Do Targeted Cancer Drugs Find Cancer Cells?
A calm, structured guide for international patients and caregivers on how targeted therapies work, what patients should expect, and how to evaluate this treatment option with confidence
Quick Answer
Targeted cancer drugs work by identifying specific molecular markers — such as mutated proteins or overexpressed receptors — that are more common in cancer cells than in healthy tissue. They bind to these targets like a key to a lock, blocking growth signals or triggering cell death. Because these markers are less active in normal cells, targeted therapies tend to spare surrounding tissue more than traditional chemotherapy — though side effects can still occur.
When patients or caregivers first hear the term “targeted therapy,” it often comes with a sense of cautious hope. Unlike chemotherapy — which affects cells throughout the body — targeted drugs are designed to go precisely to where the cancer is. But what does that actually mean in practice, and does precision always translate to fewer side effects or better outcomes?
Many international patients researching treatment options in China ask questions like: “Is targeted therapy right for my cancer?” or “How do doctors know which drug to use?” These are important questions — because targeted therapy is not a single treatment but a category of approaches that depends entirely on the molecular characteristics of each patient's tumour.
This guide walks through how targeted drugs find cancer cells, what happens when they attach, why side effects can still occur, and how to evaluate whether targeted therapy is appropriate for a specific case — including how an MDT consultation can help international patients make this decision with clarity.
How Targeted Drugs Recognise Cancer Cells — Not Healthy Ones
The core mechanism of targeted therapy relies on biological differences between cancer cells and normal cells. Cancer cells often carry specific molecular abnormalities — mutations, overexpressed proteins, or altered signalling receptors — that drive their growth. Targeted drugs are engineered to recognise and bind to these abnormalities with much greater precision than chemotherapy.
Common molecular targets in cancer
- HER2 — overexpressed in some breast and gastric cancers
- EGFR — mutated in certain lung and colorectal cancers
- ALK — rearranged in a subset of non-small cell lung cancers
- BRAF V600E — mutated in melanoma and some thyroid cancers
- PD-L1 — immune checkpoint involved in immune evasion
- BCR-ABL — fusion protein driving chronic myeloid leukaemia
- VEGFR — angiogenesis receptor in tumour blood vessel growth
- CD20 — surface marker on B-cell lymphomas
Key principle: Targeted drugs work by finding these specific markers and binding to them — much like a key fitting a particular lock. Because healthy cells express these markers at lower levels (or not at all), the drug preferentially interacts with cancer cells. However, this selectivity is not absolute: if normal cells share similar molecular pathways, some degree of off-target effect can occur.
This molecular selectivity is why targeted therapy is often described as “precision medicine.” But precision depends entirely on first identifying the right target through molecular testing — without which there is no precision at all.
What Actually Happens When a Targeted Drug Attaches to a Cancer Cell
Once a targeted drug binds to its molecular target, it interferes with cancer cell function in one or more ways. The specific mechanism depends on the type of targeted agent and the cancer being treated.
Blocking growth signals
Cancer cells rely on continuous "grow and divide" signals transmitted through surface receptors. Targeted drugs can attach to these receptors and switch off the signal — starving the cell of the instruction to proliferate.
Triggering programmed cell death (apoptosis)
Cancer cells have often bypassed the body's built-in cell death mechanisms. Some targeted drugs reactivate these pathways, prompting cancer cells to destroy themselves through normal biological processes.
Cutting off blood supply (anti-angiogenesis)
Tumours stimulate the growth of new blood vessels to sustain themselves. Certain targeted therapies inhibit this process — effectively cutting off the tumour's nutritional supply without directly attacking cells.
Delivering toxic payloads directly (antibody-drug conjugates)
A newer class of targeted agents acts like a guided missile — carrying a chemotherapy payload attached to an antibody. The antibody delivers the drug directly to cancer cells identified by the molecular target, limiting exposure to healthy tissue.
Why this matters for treatment planning: Different mechanisms suit different cancers. Knowing which mechanism is relevant to a patient's tumour type helps oncologists select the most appropriate targeted agent — and is one reason why multi-drug combination approaches are sometimes used to attack cancer through more than one pathway simultaneously.
Why Targeted Therapies Still Cause Side Effects
One of the most common misconceptions about targeted therapy is that its precision means “no side effects.” In practice, side effects are still common — though they are often different in character from chemotherapy-related effects.
Why side effects occur
- Some molecular targets exist in both cancer and normal cells
- Biological signalling pathways are shared across many tissues
- Immune and hormonal pathways can be inadvertently affected
Common side effects by drug class
- Skin reactions and rash — particularly with EGFR inhibitors
- Fatigue and reduced energy throughout treatment
- Digestive symptoms — nausea, diarrhoea, appetite change
- Liver enzyme changes — monitored through blood tests
The clinical goal is not zero side effects — it is the right balance
In clinical practice, the aim is to achieve meaningful treatment effect while keeping side effects manageable. For most patients on targeted therapy, side effects are tolerable and can often be addressed through dose adjustment, supportive management, or concurrent symptom care. Discussing expected side effects in advance — and knowing what to monitor — helps patients plan their daily life around treatment.
How Doctors Decide Whether Targeted Therapy Is Suitable
Targeted therapy is not selected based on cancer type or organ of origin alone. The decision depends primarily on the molecular profile of the tumour — and sometimes on the patient's treatment history and overall health status.
Molecular profiling of the tumour
This is the essential first step. Testing may include:
- Next-generation sequencing (NGS) of tumour tissue
- Biomarker testing — HER2, PD-L1, EGFR, ALK, and others
- Circulating tumour DNA (liquid biopsy) in some cases
- Immunohistochemistry (IHC) for receptor expression
Without confirmed molecular testing, targeted therapy cannot be correctly matched to a patient's cancer.
MDT review — the decision framework used in leading Chinese hospitals
For international patients, the decision about whether targeted therapy is appropriate is often made through a multidisciplinary team (MDT) approach. An MDT may include:
- Medical oncologist — leading systemic treatment evaluation
- Pathologist — confirming molecular findings from tumour tissue
- Radiologist — interpreting staging imaging
- Molecular specialist — reviewing genomic data for actionable targets
Key questions the evaluation must answer
- Is there a targetable mutation or marker present in this tumour?
- Is the drug for that target approved, available, or accessible through a clinical programme?
- Is targeted therapy first-line, or should it follow other treatments?
- What is the expected benefit relative to the risk and side effect profile?
- Should targeted therapy be combined with chemotherapy or immunotherapy?
For international patients considering treatment in China: If you are uncertain whether targeted therapy has been correctly evaluated for your case — or if molecular testing results are unclear — a structured MDT second opinion can help confirm whether the recommended drug is the most appropriate choice for your specific molecular profile.
Decision Framework: How to Evaluate Targeted Therapy as a Treatment Option
For international patients considering targeted therapy — whether newly diagnosed or reviewing an existing treatment plan — the following structured approach helps ensure the decision is based on complete information rather than assumption or urgency.
Confirm the molecular profile first
- Has the tumour been tested for actionable mutations?
- Has NGS or targeted biomarker testing been completed?
- Are the testing results clearly explained and documented?
Targeted therapy without confirmed molecular testing is not precision medicine — it is guesswork.
Understand treatment intent and sequence
- Is the goal curative, disease control, or symptom management?
- Is targeted therapy first-line or reserved for recurrence or resistance?
- Should chemotherapy or immunotherapy be considered first or alongside?
Treatment intent affects how aggressively targeted therapy is pursued and how it fits into the overall plan.
Evaluate drug access and availability in China
- Is the recommended targeted drug approved by the NMPA (China's drug regulator)?
- Is it accessible through standard insurance or out-of-pocket payment?
- Are investigational options available through clinical trial programmes?
Drug availability in China may differ from other countries — some agents approved abroad may be available through clinical programmes here.
Plan for resistance and ongoing monitoring
- How will treatment response be monitored during therapy?
- What happens if resistance develops?
- When should re-testing of tumour characteristics be considered?
Resistance is a known challenge with targeted therapy. Planning for it in advance is part of a comprehensive treatment strategy.
Consider a second opinion or MDT review for complex cases
- If molecular findings are unclear or have not been independently reviewed
- If recommendations between specialists differ
- If you are considering care in China and want to confirm the treatment approach
Supportive Care in China: Managing the Whole Treatment Experience
Cancer care in China may include supportive approaches alongside standard oncology treatment — including Traditional Chinese Medicine (TCM). These are not replacements for targeted therapy, but may help manage the side effects and overall stress of treatment. For international patients, these options are often integrated carefully within hospital-based care systems.
What supportive care during targeted therapy may include
- Acupuncture for fatigue, nausea, and sleep quality during treatment
- TCM herbal formulations for appetite support and digestive regulation
- Mind-body approaches to manage anxiety and emotional stress
- Nutritional guidance to help the body tolerate treatment-related changes
Important: These are supportive approaches only — used alongside, not instead of, targeted therapy or other standard oncology treatment. Any integrative therapy should be discussed with the treating oncology team to ensure it does not interfere with the targeted drug or the broader treatment plan.
For international patients interested in how integrative approaches can complement cancer treatment in China, explore how TCM-based supportive care is typically coordinated within oncology care plans — and how it is kept separate from, and complementary to, the medical treatment itself.
Caregiver Role: Supporting Decision Clarity and Daily Stability
Caregivers play a critical role when a patient is evaluating targeted therapy — particularly in cross-border care situations where language, logistics, and medical record organisation add to the complexity.
Practical ways caregivers can support the process:
- Organise medical records and test results: Pathology reports, imaging, and molecular testing results collected in order — so any second opinion or MDT review is based on the full picture, not a partial view.
- Help formulate the right questions: "Has molecular testing confirmed a targetable mutation?" and "Is there evidence this drug is appropriate for this specific cancer type and stage?" are clear, reasonable questions to ask any oncologist.
- Monitor side effects during treatment: Tracking symptoms, changes in energy, skin reactions, or digestive changes provides important clinical information and helps the care team identify when dose adjustments may be needed.
- Coordinate logistics for cross-border care: For patients travelling to China for treatment, caregivers often manage appointment coordination, travel, translation support, and communication between home and treating doctors.
The Right Starting Point
Targeted cancer therapy represents a meaningful shift toward precision-based treatment — but it is not a universal solution. Whether it is the right option depends on three things working together: correct patient selection, accurate molecular diagnosis, and well-coordinated treatment planning.
For international patients navigating these decisions — especially those considering care in China — the process begins not with choosing a drug, but with confirming the molecular evidence. A structured review of existing test results, through an MDT consultation, can often answer the most critical questions before any travel or commitment is made.
Considering Targeted Therapy? A Structured Review Can Help.
For international patients, the first step in evaluating targeted therapy is confirming whether the right molecular testing has been done — and whether the recommended drug is appropriate for the specific tumour profile. An MDT consultation can review your diagnosis, confirm whether a targetable marker exists, and help you understand whether targeted therapy is the most appropriate next step before any travel or treatment commitment is made.
Explore MDT ConsultationFrequently Asked Questions
Common questions from international patients and caregivers about targeted cancer therapy and treatment decisions in China
Do targeted cancer drugs work for all cancer types?
No. Targeted therapies only work when a cancer has specific molecular features — such as a particular mutation or overexpressed receptor — that the drug is designed to interact with. Not all tumours carry these markers. Molecular testing is essential to determine whether targeted therapy is a viable option for a specific patient.
Is targeted therapy better than chemotherapy?
Not necessarily — it depends on the cancer type, stage, and molecular profile. In some cases, targeted therapy is more effective and better tolerated than chemotherapy. In others, chemotherapy or combination approaches remain the preferred option. The decision requires a careful evaluation of the individual case, typically through MDT review.
How long does targeted therapy take to show results?
Response time varies depending on the cancer type, the specific drug, and individual patient factors. Some patients see measurable improvement within weeks; others may require months of treatment before changes appear on imaging. Regular monitoring is essential to assess response and adjust the treatment plan as needed.
Can cancer become resistant to targeted therapy?
Yes. Over time, cancer cells can develop mechanisms to bypass the targeted drug — a process called acquired resistance. This is one reason why ongoing monitoring and periodic re-testing of tumour characteristics are important during targeted therapy. When resistance develops, the treatment plan typically needs to be reassessed and adjusted.
Should international patients get a second opinion before starting targeted therapy?
In many cases, yes — especially when treatment decisions depend on complex molecular findings or when recommendations differ between specialists. A structured second opinion or MDT review can confirm whether the identified target is actionable, whether the recommended drug is the most appropriate option, and whether combination approaches should be considered.
Disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions — including whether targeted therapy is appropriate — should be made in consultation with a qualified oncologist. This article is for informational purposes only and does not constitute a clinical recommendation or promise of treatment outcomes.
Related Guides
Are There Cases of Cancer Patients Cured Without Chemotherapy?
When surgery or radiation alone may be sufficient, when targeted or hormonal therapy can replace chemotherapy, and how MDT review helps clarify necessity.
How to Make Cancer Treatment Decisions When Everything Feels Uncertain
A structured framework for international patients navigating complex treatment choices — including when MDT review adds the most value.
How Does Prostate Cancer Stage Affect Treatment Decisions?
A structured guide on how staging determines whether surgery, radiation, hormone therapy, or systemic treatment is appropriate — including targeted options.
Exploring Targeted Therapy Options in China?
If you're evaluating whether targeted therapy is the right approach for your case — or want to confirm that molecular testing has been correctly interpreted — our coordination team can help you arrange a structured MDT consultation with Chinese oncology specialists, so you can move forward with clarity.